1789 TT

ScinoPharm Investor Conference

— 2026 03 19

ScinoPharm Taiwan

Disclaimer

This material has been prepared by ScinoPharm Taiwan, Ltd. (“ScinoPharm”).

Any opinions expressed in this material are subject to change without notice as a result of using different assumptions. ScinoPharm is under no obligation to update or keep current the information contained herein. The **information contained** in this presentation **is** ScinoPharm’s **confidential** information.

Any disclosure, copying, distribution or any action taken or omitted to be taken in reliance on it is prohibited and may be unlawful.

No representation or warranty, express or implied, is or **will be made** in or in relation to, and no responsibility or liability is or will be accepted by the Company **as to**, the **accuracy or completeness** of this material and any liability therefore is hereby expressly disclaimed.

Statements made in this material include forward-looking statements, which include, without limitation, statements about the issues, plans and expectations of ScinoPharm. Without limiting the foregoing, statements including the words “believes”, “anticipates”, “plans”, “expects” and similar expressions are also forward-looking statements. Forward-looking statements reflect, among other things, management’s plans and objectives for future operations, current views with respect to future events and future economic performances and projections of various financial items. **These forward-looking statements involve known and unknown risks**, uncertainties and other factors **which may cause actual results to differ materially from those implied** by such forward-looking statements.

Agenda

01 Overview of Business Operations

02 Business Update and Outlook

03 Financial Performance



Overview of Business Operations

I. Operations Review and Key Progress

- Operation Results
  - 101.6 million USD in 2025 consolidated revenue, 4% yoy decrease; revenue in NTD was 3,163 million, 7% yoy decrease
  - NPAT at NTD 137 million with EPS at NTD 0.17
- Business progress
  - API business maintained double-digit growth in shipments
  - Drug product business achieved remarkable milestone in ANDA approval, facilitating regulatory filings and future product deployment to non U.S. markets
  - CDMO business maintained stable growth
- Factors affecting profitability
  - Product portfolio optimization and cost control improvements helped maintain a stable gross profit margin
  - Significant appreciation of NTD against USD resulted in exchange losses and was one of the main factors contributing to profit decline

II. Leverage In house Product Deployment to Maximize Product Value

- API products ~Strengthen our business foundation
  - Maintain optimized correlation between sales price and volume
  - Leverage API production experience and capacity to mitigate price competition through flexible pricing, maintaining strategic position in value chain
  - Actively expand customer base by cultivating new markets to maximize the value of the portfolio
- Proprietary Drug Products ~Drive future growth
  - Focus on high value drug device combination products, targeting therapeutic areas such as oncology, hematology, metabolic disorders, and CNS diseases
  - Establish a stable supply capacity for products with ANDA approval to support long-term sales
  - Accelerate product line enhancement and potential market expansion to drive future growth
  - Leverage strategic partnerships to co-develop 505(b)(2) projects

III. Expand CDMO Footprint to Create Growth Momentum

- Core Position
  - Focus on the peptide, steroid, and cytotoxic product sectors
- Capacity Building
  - Leverage and continually improve our R&D and manufacturing capabilities
  - Actively participate in industry exhibitions to showcase our technical strengths to increase market exposure and customer reach
- Drive Growth
  - Attract collaborations with innovative drug companies to support realization of their product vision and transforming innovation into value
  - Expand our contract manufacturing portfolio, diversify the customer base, and provide comprehensive, fully integrated services



Business Update and Outlook

Strengthening API Business

- Completed development of 80 products and DMF filings, of which 40 products have supported finished drug products in commercial markets. Continue to closely monitor customers' registration as well as commercial launches
- Integrate our API experience and capacity in production to respond to price competition with flexible pricing strategies, secure existing market share and proactively follow up with new customers and new markets to maximize the value of our proprietary API portfolio
- Expand product portfolio and pursue strategic partnerships with downstream formulation customers to secure supply opportunities and market share after commercial launch



Accelerating Drug Product Business Development

- 21 drug products have been developed, of which 4 products have obtained approvals in US and TW, with 3 products under review
- 2 approved drug products for the treatment of multiple sclerosis and multiple myeloma are in the process for product launch in US and TW market, respectively
- Accelerate the approval of proprietary injectable products in US and TW and proactively expand non US market deployment

Therapeutic Areas	Project Numbers	Indication	Under Development	Technical Package Ready	Under Registration	Approved
Oncology	11	• Multiple Myeloma • Leukemia • Myelodysplastic Syndromes • Oncology	1 1	 1 6		1 1
CNS	2	• Multiple Sclerosis • Reversal of Neuromuscular Blockade		 1		1
Cardiovascular	2	• Thromboembolic Disorders • Medical Imaging Agents		 1		1
Metabolism	6	• Osteoporosis • Diabetes Mellitus • Chronic Weight Management	 1 1	 1	1 1 1 *	

Note: The number mark in blue indicates the registration submission both in US and TW have been approved or are under review.

* Submitted to FDA for ANDA approval in 2026/02

Expanding CDMO Services

- 56 CDMO active projects, 3 projects at R&D pre-clinical stage and 1 project at clinical phase I stage were added to API CDMO projects portfolio in 2025
- Increase international exposure and customer reach, pursue collaboration opportunities and maintain growth in CDMO services
- In addition to focuses on specialized areas such as peptides, steroids, and cytotoxic products, leverage our injectable manufacturing capabilities to expand DP CDMO business and enrich our injectable formulation CDMO product line







Financial Performance

Consolidated Income Statement

NTD Million except for EPS	2025		YoY	2024	
Revenue	3,163	100%	-7%	3,406	100%
Gross Profit	1,096	34%	-16%	1,300	38%
Operating Expenses	(987)	(31%)	1%	(979)	(29%)
Operating Profit	109	3%	-66%	321	9%
Net Profit before Tax	147	4%	-64%	413	12%
Net Profit after Tax	137	4%	-60%	339	10%
EPS (NTD)	0.17	-	-	0.43	-

Sales Distribution – By Business





Note：Starting from 2024, statistics will be listed using a new classification method

Unit: USD/M

	API	CDMO	Drug Product
FY 2025 Sales	69.4	32.2	0
YoY	-6.8%	5.1%	-100.0%

Sales Distribution – By Indication





Unit: USD/M

	Oncology	CNS	Others
FY 2025 Sales	65.6	24.9	11.1
YoY	0.2%	-4.1%	-24.3%

Consolidated Balance Sheet

NTD Million	2025/12/31		2024/12/31	
Cash and Cash Equivalents	3,110	26%	4,166	35%
Accounts Receivable	612	5%	604	5%
Inventories	1,637	14%	1,673	14%
Property, Plant & Equipment	3,409	29%	3,739	32%
Financial Assets	1,368	12%	70	1%
Other Current/Non-Current Assets	1,722	14%	1,691	13%
Total Assets	**11,858**	**100%**	**11,943**	**100%**
Financial Debt	131	1%	36	0%
Other Current Liabilities	579	5%	732	6%
Other Non-Current Liabilities	623	5%	649	5%
Total Liabilities	**1,333**	**11%**	**1,417**	**12%**
Total Shareholders' Equities	**10,525**	**89%**	**10,526**	**88%**

Consolidated Cash Flow Statement

NTD million	2025	2024	Dif.
From Operating Activities	**596**	**751**	**-155**
Depreciation & Amortization	517	488	29
From Investing Activities	**(1,452)**	**(293)**	**-1,159**
Acquisition of financial assets	(1,156)	-	-1,156
Capital Expenditure	(296)	(300)	4
From Financing Activities	**(202)**	**(245)**	**-43**
Effect of foreign exchange rate changes	2	11	-9
Net Change in Cash	**(1,056)**	**224**	**-1,280**
Beginning Balance	4,166	3,942	224
Ending Balance	**3,110**	**4,166**	**-1,056**



Q & A

Appendix
Company Overview

ScinoPharm at a Glance

- Est. 1997 in Taiwan with R&D/CGMP plants in Tainan and Changshu, China plus marketing forces in Tainan, Shanghai and Tokyo
- Specializes in providing R&D and CGMP manufacturing of APIs (cytotoxic/steroid) and injectable drug products
- 80 generic APIs in portfolio with 40 referred and approved ANDAs/NDAs*
  - 986 active DMFs worldwide*
- 200+ contract projects with 14 approved/launched (12 NCEs) and 4 in phase 3 for NDA/MAA filing within 1-3 years*
- API plant certified by key international regulators - US FDA, EMA, EDQM, Australian TGA, Japanese PMDA, Korea KFDA, Mexico COFEPRIS and German Authority. In November 2024, we passed Brazilian ANVISA 1st on-site GMP inspection with zero defect and maintained its exceptional track record of 5 consecutive zero defect inspections by the US FDA
- Injectable plant certified by US FDA and TFDA

*Data As of 2026/01/31

For every life. With every trust.

www.scinopharm.com **1789 TT**